IL15 and neoplasm: This is the case of therapeutic abs to tumor Ag, which can induce ADCC, or bi- and tri-specific Killer Engagers (BiKE and TRiKE), engineered molecules simultaneously targeting tumor Ag, engaging CD16 on NK cells, and (in the case of TRiKE) presenting IL-15 to support NK cell persistence and expansion [10,56].